A process for analysing chromosome regions and interactions relating to prognosis of prostate cancer or DLBCL.

A process for analysing chromosome regions and interactions relating to prognosis of prostate cancer or DLBCL.

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

The invention relates to methods of detecting mutations associated with the Ras homologue gene family member (RHOA) gene, and diagnosing conditions associated with these mutations, using Competitive allele-specific TaqMan polymerase chain reaction (cast-PCR). The invention also extends to the products used to detect mutations, and their use in diagnosis.

The invention relates to methods of detecting mutations associated with the Ras homologue gene family member (RHOA) gene, and diagnosing conditions associated with these mutations, using Competitive allele-specific TaqMan polymerase chain reaction (cast-PCR). The invention also extends to the products used to detect mutations, and their use in diagnosis.

The present invention provides a method for obtaining tumour nucleic acid for sequencing, comprising providing a medium containing tumour cells shed from a solid tumour sample into the medium ex vivo and/or released during mechanical disruption of a solid tumour sample and extracting nucleic acid from the shed and/or released tumour cells tumour cells.

The present invention provides a method for obtaining tumour nucleic acid for sequencing, comprising providing a medium containing tumour cells shed from a solid tumour sample into the medium ex vivo and/or released during mechanical disruption of a solid tumour sample and extracting nucleic acid from the shed and/or released tumour cells tumour cells.

Methods of treatment based on a breast cancer's biomolecule response to targeted treatment are provided. Expression levels of various biomolecules or histological assessment of infiltrating immune cells after initiation of human epidermal growth factor receptor 2 (HER2) targeted treatment can be used to determine whether a breast cancer will achieve a pathologic complete response. Based on likelihood of a pathologic complete response, a breast cancer can be treated accordingly.

Methods of treatment based on a breast cancer's biomolecule response to targeted treatment are provided. Expression levels of various biomolecules or histological assessment of infiltrating immune cells after initiation of human epidermal growth factor receptor 2 (HER2) targeted treatment can be used to determine whether a breast cancer will achieve a pathologic complete response. Based on likelihood of a pathologic complete response, a breast cancer can be treated accordingly.